Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Monte Rosa Therapeutics (GLUE) Change in Receivables (2023 - 2025)

Monte Rosa Therapeutics' Change in Receivables history spans 3 years, with the latest figure at -$365000.0 for Q4 2025.

  • For Q4 2025, Change in Receivables rose 13.51% year-over-year to -$365000.0; the TTM value through Dec 2025 reached $4.4 million, up 1433.43%, while the annual FY2025 figure was $4.4 million, 1433.43% up from the prior year.
  • Change in Receivables reached -$365000.0 in Q4 2025 per GLUE's latest filing, down from $4.8 million in the prior quarter.
  • In the past five years, Change in Receivables ranged from a high of $9.0 million in Q2 2024 to a low of -$8.9 million in Q3 2024.
  • Average Change in Receivables over 3 years is $183166.7, with a median of -$177500.0 recorded in 2024.
  • Peak YoY movement for Change in Receivables: crashed 299.01% in 2024, then skyrocketed 12250.0% in 2025.
  • A 3-year view of Change in Receivables shows it stood at $336000.0 in 2023, then tumbled by 225.6% to -$422000.0 in 2024, then rose by 13.51% to -$365000.0 in 2025.
  • Per Business Quant, the three most recent readings for GLUE's Change in Receivables are -$365000.0 (Q4 2025), $4.8 million (Q3 2025), and -$1.2 million (Q2 2025).